MarketLens
Sign Up

Has ADC Therapeutics' ZYNLONTA Delivered on its Phase 3 Promise

3 months ago
SHARE THIS ON:

Has ADC Therapeutics' ZYNLONTA Delivered on its Phase 3 Promise

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News5 days ago

Can KT-621 Mark a Turning Point for Kymera Therapeutics?

Kymera Therapeutics' KT-621 is advancing in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027, marking a possible pipeline turning point.
Stock News3 weeks ago

ADC Therapeutics Q2 Earnings Call Highlights

ADC Therapeutics' ZYNLONTA generated $18.6M in Q2 2026 net product revenue, up from $18.1M a year earlier, as executives said commercial performance stayed broadly consistent with recent quarters.
Stock News1 months ago

Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?

BMY filed for FDA approval of mezigdomide in relapsed/refractory multiple myeloma, advancing its CELMoD protein degrader pipeline.

Breaking News

View All →

Top Headlines

View More →
Stock News45 minutes ago

Prediction: Sept. 10 Will Be a Big Day for Nvidia Shareholders.

Stock News2 hours ago

QQQ vs QQQM: Same Index, Same Stocks, Different Fee – and the Math Says One Leaves You Thousands Richer

Stock News2 hours ago

Qualcomm CFO on Amazon AI Deal, Data Center Strategy

Stock News3 hours ago

Meta Targets Mass Market Automation With New Muse AI Agent

Stock News3 hours ago

Nvidia vs. Broadcom: Comparing Recent Quarterly Revenue Trajectories